Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Alpha Cognition Inc ACOG

Alpha Cognition Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is engaged in developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease and Cognitive Impairment with mild Traumatic Brain Injury (mTBI). The Company’s pipeline includes ALPHA-1062, ALPHA-0602, and ALPHA-0702 and ALPHA-0802 (GEMs). The Company’s ALPHA-1062... see more

NDAQ:ACOG - Post Discussion

Alpha Cognition Inc > Im expecting big things for $ACOG.v / $ACOGF
View:
Post by stockpatrol on Mar 04, 2022 6:47pm

Im expecting big things for $ACOG.v / $ACOGF

Im expecting big things for $ACOG.v / $ACOGF 
 
https://twitter.com/Canadasmallcap/status/1499805946960244738 
 
The preclinical data for ALPHA-1062 is looking optimistic that ALPHA-1062 could be an effective treatment for traumatic brain injury 
 
Once this revolutionary drug gets FDA approval its go time for $ACOG.v
Comment by Castortroy2020 on Mar 06, 2022 10:16pm
what's the date for FDA approval?
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities